A problem for biopharmaceutical companies comes as degraded proteins lead to ineffective and possibly dangerous medicines for their clients. Drug companies work on formulation development to protect ...

Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), recently announced the launch of Altru-CON, a high-concentration ...

Nearly half of all drug shortages in 2022 were caused by quality issues or manufacturing delays, according to the Center for Drug Evaluation and Research (CDER). Evaluating the critical quality ...

Forced degradation studies involve exposing a drug substance to harsher conditions than the product would be expected to experience and determining at what point and how it degrades. Identifying ...

An important parameter is the aggregation pattern when exposed to thermal stress, as this can give us a better understanding as needed for problem-solving during formulation development. To assess the ...

Altru-CON harnesses proprietary excipient blends and expertise to maximize drug delivery and stability through high-concentration formulation.The platform can reduce IND timelines to under nine ...

WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent ...

Vectura Limited has signed an agreement with GlaxoSmithKline plc (GSK) to collaborate on evaluating Vectura's Aerocine and associated powder formulation technologies in dry powder inhaler devices for ...

Their findings show that the dramatic increase in surface tension that affects the production of various pharmaceutical and cosmetic formulations is caused by the comprehensive aggregation of active ...

Chemical engineers have devised a simpler process for incorporating hydrophobic drugs into tablets or other drug formulations, using nanoemulsions. With this method, it may be possible to make many ...

With topical formulations, it may be possible to deliver the active ingredient to a specific site and avoid first-pass metabolism, changing drug concentrations in the bloodstream and patient-specific ...

TOKYO--(BUSINESS WIRE)--Asahi Kasei has established industrial manufacturing technology for hyaluronic acid (HA) nanogel* as a new pharmaceutical excipient, and is providing samples to prospective ...